ATI RN
ATI Pharmacology Proctored Exam 2023
1. A client has been prescribed Phenelzine for depression. Which of the following indicates that the client has developed an adverse effect of this medication?
- A. Orthostatic hypotension
- B. Hearing loss
- C. Gastrointestinal bleeding
- D. Weight loss
Correct answer: A
Rationale: Orthostatic hypotension is a known adverse effect of Phenelzine, a monoamine oxidase inhibitor (MAOI) used for depression. It is caused by a sudden drop in blood pressure when changing positions, leading to symptoms like dizziness or fainting. Monitoring for orthostatic hypotension is crucial during Phenelzine therapy to prevent complications. Choices B, C, and D are incorrect because hearing loss, gastrointestinal bleeding, and weight loss are not typically associated with Phenelzine use.
2. A client informs the nurse about taking Gingko Biloba. Which of the following medications is contraindicated for a client taking Gingko Biloba?
- A. Acetaminophen
- B. Warfarin
- C. Digoxin
- D. Lisinopril
Correct answer: B
Rationale: The correct answer is B, Warfarin. Warfarin is contraindicated for a client taking Gingko Biloba due to the potential interaction. Gingko Biloba can suppress coagulation and increase the risk of bleeding or hemorrhage when taken with anticoagulants like Warfarin. Acetaminophen (choice A), Digoxin (choice C), and Lisinopril (choice D) do not have significant interactions with Gingko Biloba.
3. A healthcare provider is completing a client's medical history. The client takes Simvastatin. The healthcare provider should identify which of the following disorders as a contraindication to adding Ezetimibe to the client's medications?
- A. History of severe constipation
- B. History of hypertension
- C. Active hepatitis C
- D. Type 2 diabetes mellitus
Correct answer: C
Rationale: Ezetimibe is contraindicated in patients with active moderate-to-severe liver disorders, such as active hepatitis C, especially when they are already taking a statin like simvastatin. This combination can increase the risk of liver problems and is not recommended due to the potential for further liver damage. Choices A, B, and D are not directly contraindications for adding Ezetimibe to the client's medications.
4. A client is taking Glipizide to treat Diabetes Mellitus. Which of the following laboratory tests should the nurse monitor to evaluate the effectiveness of this medication?
- A. Cholesterol level.
- B. Hematocrit.
- C. Blood glucose level.
- D. Calcium level.
Correct answer: C
Rationale: The correct answer is C: Blood glucose level. Monitoring the client's blood glucose level is crucial when taking Glipizide, a medication used to lower blood glucose levels in individuals with Diabetes Mellitus. By monitoring the blood glucose level, the nurse can evaluate the effectiveness of the medication in managing the client's condition. Choices A, B, and D are incorrect as they are not directly related to assessing the effectiveness of Glipizide in treating Diabetes Mellitus. Cholesterol level, hematocrit, and calcium level may be important for other aspects of the client's health but are not the primary indicators of Glipizide's effectiveness.
5. Which of the following is NOT an opioid or NSAID?
- A. Morphine
- B. Ibuprofen
- C. Hydromorphone
- D. Acetaminophen
Correct answer: D
Rationale: Acetaminophen is the correct answer as it is not classified as an opioid or NSAID. Acetaminophen is considered a non-opioid analgesic, which means it works by a different mechanism than opioids and NSAIDs to relieve pain and reduce fever. Morphine, hydromorphone, and ibuprofen, on the other hand, are classified as opioids or NSAIDs. Morphine and hydromorphone are opioids, while ibuprofen is an NSAID (Nonsteroidal Anti-Inflammatory Drug), all of which work through different mechanisms compared to acetaminophen.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access